| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 60838 | irinotecan | ALOX5, CACNG4, CACNG5, CYP2D6, FBP1, IAPP, NDUFS5, POLA1, SDHD, TLR4, TOP1, TOP1MT | antineoplastic agent, Dehydration, Heart Diseases, Neutropenia, Pleural effusion disorder, Cardiac disorder, Pleural effusion, Malignant Neoplasms, Glioma, Lymphoma, Mesothelioma, Cervix carcinoma, Malignant neoplasm of pancreas, Malignant neoplasm of esophagus, Carcinoma of lung, Colorectal Cancer, Neoplasm malignant, Non-Hodgkin_s lymphoma, Neoplasm, Pancreatic carcinoma, Oesophageal carcinoma, Lung neoplasm malignant, Colorectal cancer, Small cell carcinoma of lung, Astrocytoma, anaplastic, Ewing_s sarcoma, Non-small cell lung cancer |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| irinotecan | SLC25A15 (Q9Y619) | 0.0791 | 0 | - |
| irinotecan | IL17A (Q16552) | 0.0791 | 0 | - |
| irinotecan | MYDGF (Q969H8) | 0.079 | 0 | - |
| irinotecan | FKBP1A (P62942) | 0.0788 | 0 | - |
| irinotecan | TRPC5 (Q9UL62) | 0.0788 | 0 | - |
| irinotecan | NR2F1 (P10589) | 0.0785 | 0 | - |
| irinotecan | GLS2 (Q9UI32) | 0.0785 | 0 | - |
| irinotecan | ESRRB (O95718) | 0.0784 | 0 | - |
| irinotecan | ESRRG (P62508) | 0.0784 | 0 | - |
| irinotecan | Q9PRS8 | 0.0782 | 0 | - |
| irinotecan | TFF1 (P04155) | 0.0781 | 0 | - |
| irinotecan | MMP3 (P08254) | 0.0781 | 0 | - |
| irinotecan | NPC1L1 (Q9UHC9) | 0.078 | 0 | - |
| irinotecan | P18871 | 0.078 | 0 | - |
| irinotecan | Q59487 | 0.078 | 0 | - |
| irinotecan | CCNL1 (Q9UK58) | 0.0779 | 0 | - |
| irinotecan | O02697 | 0.0779 | 0 | - |
| irinotecan | HRH2 (P25021) | 0.0779 | 0 | - |
| irinotecan | DDR1 (Q08345) | 0.0778 | 0 | - |
| irinotecan | NDUFC1 (O43677) | 0.0775 | 0 | - |
| irinotecan | M6PR (P20645) | 0.0774 | 0 | - |
| irinotecan | DCK (P27707) | 0.0773 | 0 | - |
| irinotecan | RBP4 (P02753) | 0.0773 | 0 | - |
| irinotecan | CCL2 (P13500) | 0.0771 | 0 | - |
| irinotecan | PSMB9 (P28065) | 0.077 | 0 | - |
| irinotecan | CYP2R1 (Q6VVX0) | 0.0769 | 0 | - |
| irinotecan | P0AEK4 | 0.0769 | 0 | - |
| irinotecan | IL36A (Q9UHA7) | 0.0768 | 0 | - |
| irinotecan | KCNN3 (Q9UGI6) | 0.0767 | 0 | - |
| irinotecan | SLC25A4 (P12235) | 0.0766 | 0 | - |
| irinotecan | CYP4Z1 (Q86W10) | 0.0765 | 0 | - |
| irinotecan | P35563 | 0.0765 | 0 | - |
| irinotecan | TUBB3 (Q13509) | 0.0764 | 0 | - |
| irinotecan | HTR3E (A5X5Y0) | 0.0763 | 0 | - |
| irinotecan | CACNG8 (Q8WXS5) | 0.0762 | 0 | - |
| irinotecan | ANXA1 (P04083) | 0.0762 | 0 | - |
| irinotecan | OSBP (P22059) | 0.0761 | 0 | - |
| irinotecan | KCNH7 (Q9NS40) | 0.0761 | 0 | - |
| irinotecan | Q63931 | 0.0759 | 0 | - |
| irinotecan | P0A076 | 0.0759 | 0 | - |
| irinotecan | INSR (P06213) | 0.0758 | 0 | - |
| irinotecan | FABP4 (P15090) | 0.0757 | 0 | - |
| irinotecan | BGLAP (P02818) | 0.0757 | 0 | - |
| irinotecan | GMPR2 (Q9P2T1) | 0.0757 | 0 | - |
| irinotecan | MMP8 (P22894) | 0.0756 | 0 | - |
| irinotecan | SEC14L4 (Q9UDX3) | 0.0756 | 0 | - |
| irinotecan | P10930 | 0.0756 | 0 | - |
| irinotecan | Q61616 | 0.0756 | 0 | - |
| irinotecan | IL21 (Q9HBE4) | 0.0755 | 0 | - |
| irinotecan | IGF1R (P08069) | 0.0755 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| irinotecan | GO:0006281 DNA repair | 1 | 1 |
| irinotecan | GO:0008283 cell population proliferation | 1 | 1 |
| irinotecan | GO:0001570 vasculogenesis | 0.6667 | 1 |
| irinotecan | GO:0010833 telomere maintenance via telomere lengthening | 0.5 | 0 |
| irinotecan | GO:0031570 DNA integrity checkpoint | 0.5 | 0 |
| irinotecan | GO:0001525 angiogenesis | 0.3333 | 0 |
| irinotecan | GO:0016477 cell migration | 0.256 | 0 |
| irinotecan | GO:0007155 cell adhesion | 0.2299 | 0 |
| irinotecan | GO:0008283 cell population proliferation (viability) | 0.1042 | 0 |
| irinotecan | GO:0016049 cell growth | 0.0147 | 0 |
| irinotecan | GO:0008219 cell death | 0 | 0 |
| irinotecan | GO:0006954 inflammatory response | 0 | 0 |
| irinotecan | GO:0071456 cellular response to hypoxia | 0 | 0 |
| irinotecan | GO:0006096 glycolytic process | 0 | 0 |
| irinotecan | GO:0007049 cell cycle | 0 | 0 |
| irinotecan | GO:0006915 apoptotic process | 0 | 0 |
| irinotecan | GO:0002418 immune response to tumor cell | 0 | 0 |
| irinotecan | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| irinotecan | Cancer(general) | 0.6007 | 0 | - |